Literature DB >> 29860116

Intestinal permeability determinants of norfloxacin in Ussing chamber model.

Cassiana Mendes1, Gabriela C Meirelles2, Marcos A S Silva3, Gilles Ponchel2.   

Abstract

Recently, many efforts are taken to identify the intestinal uptake and efflux transporters since they are responsible for the absorption of many drugs as their interactions. Norfloxacin (NFX) is a fluoroquinolone that presents low solubility and low permeability, and as a consequence, low bioavailability. In this context, the aim of this study is evaluate for the first time the intestinal permeability mechanisms of NFX by Ussing chamber model. The low permeation of NFX at low temperature, where the efflux pumps are not active, reveals that NFX permeation is transporter-dependent. The permeation study at different level of intestine demonstrated that NFX passage is in the decrescent order: ileum > jejunum > duodenum > colon, probably attributed to transporters that are expressed differently along the intestinal tract. NFX intestinal flow was evaluated in the presence of many inhibitors and substrates to identify the uptake and efflux transporters implicate in NFX permeability mechanism. It could be observed that BCRP and MRPs are involved in the NFX efflux and PEPT1, PMAT and OCT in the NFX uptake transport. Furthermore, this work revealed that NFX has itself an affinity for OCTN and OATP, demonstrating that NFX could inhibit these transporters and influence the absorption of other drugs. The updated description of NFX intestinal permeability factors could contribute to the development of rational pharmaceutical formulations that could circumvent the efflux problems and consequently improve NFX biopharmaceutical properties and avoid drug-drug interactions.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Budesonide (PubChem CID: 5281004); Cyclosporine (PubChem CID: 5284373); Efflux; Intestinal permeability; Levofloxacin (PubChem CID: 149096); Lisinopril (PubChem CID: 5362119); MK-571 (PubChem CID: 5281888); Norfloxacin; Norfloxacin (PubChem CID: 4539); Novobiocin (PubChem CID: 54675769); Quinidine (PubChem CID: 441074); Rhodamine 123 (PubChem CID: 65217); Transporter; Uptake; Ussing chamber; Verapamil (PubChem CID: 2520)

Mesh:

Substances:

Year:  2018        PMID: 29860116     DOI: 10.1016/j.ejps.2018.05.030

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  2 in total

Review 1.  Prophylactic Antibiotics in Cirrhosis: Are They Promoting or Preventing Infections?

Authors:  Guadalupe Garcia-Tsao
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-10-09

Review 2.  Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery.

Authors:  Maisarah Azman; Akmal H Sabri; Qonita Kurnia Anjani; Mohd Faiz Mustaffa; Khuriah Abdul Hamid
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.